An interim final rule placing brivaracetam (BRV) in Schedule V has been adopted without change, the Drug Enforcement Administration announced (82 Fed. Reg. 13067; March 9, 2017).  Also referred to as Briviact or UCB-34714, BRV is a new molecular entity approved by the U.S. Food and Drug Administration on March 28, 2016, as an add-on treatment to other medications for partial onset... Read More